Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Share-based Compensation (2022 - 2025)

Gossamer Bio's Share-based Compensation history spans 4 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 41.63% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $10.6 million, down 48.81%, while the annual FY2025 figure was $10.6 million, 48.81% down from the prior year.
  • Share-based Compensation reached $2.9 million in Q4 2025 per GOSS's latest filing, up from $2.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $11.4 million in Q4 2022 to a low of $2.4 million in Q1 2025.
  • Average Share-based Compensation over 4 years is $6.4 million, with a median of $5.9 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: fell 17.69% in 2024, then crashed 58.61% in 2025.
  • A 4-year view of Share-based Compensation shows it stood at $11.4 million in 2022, then tumbled by 47.31% to $6.0 million in 2023, then dropped by 17.69% to $5.0 million in 2024, then tumbled by 41.63% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Share-based Compensation are $2.9 million (Q4 2025), $2.7 million (Q3 2025), and $2.6 million (Q2 2025).